Vancomycin Neupharm(Vancomicina Azevedos) , 500 mg
powder for concentrate for solution for infusion
Vancomycinum
Vancomycin Neupharm and Vancomicina Azevedos are different trade names for the same medicine.
Vancomycin is an antibiotic belonging to the class of glycopeptide antibiotics. The action of vancomycin involves killing certain bacteria that cause infections. Vancomycin in powder form is used to prepare a concentrate for solution for infusion or oral solution. Vancomycin is used in all age groups in the form of an infusion (drip) to treat the following severe infections:
Vancomycin may be given orally to adults and children to treat infection of the mucous membrane of the small and large intestine associated with damage to the mucous membrane (pseudomembranous colitis) caused by the bacteria Clostridium difficile.
After injecting vancomycin into the eye, severe side effects have occurred, which can lead to loss of vision. Before starting treatment with Vancomycin Neupharm, you should discuss this with your doctor, hospital pharmacist or nurse if:
Severe skin reactions have occurred with vancomycin treatment, including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). If the patient notices any of the symptoms described in section 4, they should stop taking vancomycin and see a doctor immediately. During treatment with Vancomycin Neupharm, you should discuss this with your doctor, hospital pharmacist or nurse if:
Vancomycin will be used with special caution in premature infants and young infants, as their kidneys are not fully developed, which can lead to the accumulation of vancomycin in the blood. In this age group, blood tests may be necessary to monitor the concentration of vancomycin in the blood. The simultaneous administration of vancomycin and anesthetics in children is associated with the occurrence of skin redness (flushing) and allergic reactions. Additionally, the simultaneous use of other medications, such as aminoglycoside antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs, e.g., ibuprofen), or amphotericin B (a medication used to treat fungal infections), may increase the risk of kidney damage, and therefore, more frequent blood tests and kidney function tests may be necessary.
You should tell your doctor, pharmacist or nurse about all the medicines you are taking, have recently taken, or plan to take. You should be particularly careful if you are taking other medicines that may interact with vancomycin, such as:
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, you should ask your doctor for advice before taking this medicine. Vancomycin can be used during pregnancy only if absolutely necessary, when the doctor believes that the benefits of treatment outweigh the risks. The doctor will recommend monitoring the vancomycin concentration in the serum to minimize the risk of toxic effects on the fetus. Vancomycin passes into breast milk, and therefore, it can be used during breastfeeding only if other antibiotics have been ineffective. If the mother's treatment with vancomycin is absolutely necessary, the doctor will carefully monitor the condition of the infant or recommend stopping breastfeeding. There are no fertility studies.
Vancomycin Neupharm has a negligible effect on the ability to drive and use machines.
The patient will receive Vancomycin Neupharm administered by medical staff during their hospital stay. The doctor will decide what dose of the medicine the patient should receive each day and how long the treatment should last.
The dose administered will depend on:
Intravenous administration
The dose will be determined based on the patient's body weight. The usual dose used in infusion is 15 to 20 mg per kilogram of body weight. This dose is usually administered every 8 to 12 hours. In some cases, the doctor may decide to use a loading dose of up to 30 mg per kilogram of body weight. The maximum daily dose of vancomycin should not exceed 2 grams.
Children from the first month of life and children under 12 years of age The dose will be determined based on the patient's body weight. The usual dose used in infusion is 10 to 15 mg per kilogram of body weight. This dose is usually administered every 6 hours. Premature infants and full-term newborns (from birth to 27 days of postnatal age) The dose will be calculated based on post-conceptional age [the time from the first day of the last menstrual period to birth (gestational age) plus the time from birth (postnatal age)].
Vancomycin may be administered orally to adults and adolescents (12 years and older) The recommended dose is 125 mg every 6 hours. In some cases, the doctor may decide to use a higher daily dose, up to 500 mg every 6 hours. The maximum daily dose should not exceed 2 grams. If the patient has had other disorders (mucous membrane infection), a different dose and duration of treatment may be necessary.
Newborns, infants, and children under 12 years of age The recommended dose is 10 mg per kilogram of body weight. This dose is usually administered every 6 hours. The maximum daily dose should not exceed 2 grams.
Intravenous infusion (drip) means that the medicine flows from a bottle or infusion bag through a tube into one of the patient's veins. The doctor or nurse will always administer vancomycin into the blood, not into the muscle. Vancomycin will be administered into a vein over at least 60 minutes. If used to treat gastrointestinal disorders (so-called pseudomembranous colitis), the medicine must be administered orally (the patient will take the medicine by mouth). Instructions for preparing the solution before administration can be found in "Information intended for healthcare professionals only" at the end of the leaflet.
The duration of treatment depends on the type of infection the patient has and may last for several weeks. The duration of treatment may vary depending on the patient's response to treatment. During treatment, the patient may have blood tests and urine analysis, and may also have a hearing test to check for possible side effects. If you have any further doubts about using this medicine, you should consult a doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
inform their doctor.
Common side effects(may affect up to 1 in 10 people):
Uncommon side effects(may affect up to 1 in 100 people):
Rare side effects(may affect up to 1 in 1,000 people):
Very rare side effects(may affect up to 1 in 10,000 people):
Frequency not known(frequency cannot be estimated from the available data)
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor, pharmacist or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. By reporting side effects, you can help provide more information on the safety of this medicine.
The active substance of the medicine is vancomycin. Each vial contains 500 mg of vancomycin in the form of vancomycin hydrochloride. Vancomycin Neupharm does not contain any other ingredients.
Vancomycin Neupharm is a white or slightly brown powder, placed in a vial made of colorless type I glass, with a rubber stopper and an aluminum cap, in a cardboard box. The packaging contains 10 vials. For more detailed information, you should contact the marketing authorization holder or the parallel importer.
Laboratórios Azevedos – Indústria Farmacêutica, S.A. Estrada Nacional 117-2, Alfragide 2614-503 Amadora Portugal
Sofarimex – Indústria Química e Farmacêutica, S.A. Av. das Indústrias, Alto de Colaride 2735-213 Cacém Portugal
Neupharm Sp. z o.o. ul. Ługowa 85 96-320 Mszczonów
LABOR Przedsiębiorstwo Farmaceutyczno-Chemiczne Sp. z o.o. ul. Długosza 49 51-162 Wrocław GP LABEL Ostrowski spółka jawna ul. Obywatelska 128/152 94-104 Łódź Portuguese marketing authorization number:5623707
[Information about the trademark]
The medicinal product should be administered by intravenous infusion or orally. It should not be administered by rapid intravenous injection (bolus) or intramuscularly. Intravenous administrationThe initial dose should be determined based on the total body weight. Subsequent dose modifications should be based on the serum concentration of vancomycin, with the aim of achieving the target therapeutic concentration. When determining subsequent doses and intervals, kidney function should also be taken into account. The following dosing regimens are recommended: Patients 12 years and olderThe recommended dose is 15 to 20 mg/kg every 8 to 12 hours (do not exceed 2 grams per dose). In the case of patients in severe condition, a loading dose of 25-30 mg/kg may be used to facilitate rapid achievement of the target minimum vancomycin concentration in the serum. Infants from the first month of life and children under 12 years of ageThe recommended intravenous dose is 10 to 15 mg/kg every 6 hours. Newborns born at term (from birth to 27 days of postnatal age) and premature infants (from birth to the expected date of delivery plus 27 days)To determine the dosing regimen for newborns, you should consult a doctor experienced in treating newborns. One possible dosing regimen for vancomycin in newborns is presented in the table below: PMA: post-conceptional age [the time from the first day of the last menstrual period to birth (gestational age) plus the time from birth (postnatal age)].
PMA (weeks) | Dose (mg/kg) | Dosing interval (hours) |
<29 | 15 | 24 |
29-35 | 15 | 12 |
>35 | 15 | 8 |
Indication | Duration of treatment |
Complicated skin and soft tissue infections
| 7 to 14 days 4 to 6 weeks* |
Bone and joint infections | 4 to 6 weeks** |
Community-acquired pneumonia | 7 to 14 days |
Hospital-acquired pneumonia, including ventilator-associated pneumonia | 7 to 14 days |
Infective endocarditis | 4 to 6 weeks*** |
Acute bacterial meningitis | 10 to 21 days |
* Continue until it is no longer necessary to remove necrotic tissue, the patient's clinical condition improves, and the patient has not had a fever for 48 to 72 hours. ** In the case of prosthetic joint infections, consider longer cycles of oral suppressive therapy with appropriate antibiotics. *** The duration and need for combination therapy depend on the type of valve and microorganism. Adult patientsDose modifications in adult patients may be based on the estimated glomerular filtration rate (eGFR) based on the following formula: Men: [weight (kg) x 140 - age (years)] / 72 x serum creatinine concentration (mg/dl) Women: 0.85 x the value calculated using the above formula The usual initial dose for adult patients is 15 to 20 mg/kg; this dose can be administered every 24 hours to patients with a creatinine clearance of 20 to 49 ml/min. In the case of patients with severe kidney problems (creatinine clearance below 20 ml/min) or patients undergoing renal replacement therapy, the appropriate dosing intervals and subsequent doses depend largely on the RRT procedure used and should be determined based on the vancomycin serum concentration and residual renal function. Depending on the clinical situation, it may be considered to withhold the next dose until the vancomycin concentration in the blood is determined. In critically ill patients with kidney problems, the initial loading dose (25 to 30 mg/kg) should not be reduced. Children and adolescentsDose modifications in children aged 1 year and older and adolescents may be based on the estimated glomerular filtration rate (eGFR) based on the modified Schwartz formula: eGFR (ml/min/1.73 m^2) = (height in cm x 0.413) / serum creatinine concentration (mg/dl) eGFR (ml/min/1.73 m^2) = (height in cm x 36.2 / serum creatinine concentration (μmol/l) For newborns and infants under 1 year of age, you should consult an expert, as the Schwartz formula does not apply to such patients. The approximate dosing recommendations for children and adolescents presented in the table below are subject to the same principles as the recommendations for adult patients.
GFR (ml/min/1.73 m^2) | Intravenous dose | Frequency |
50-30 | 15 mg/kg | Every 12 hours |
29-10 | 15 mg/kg | Every 24 hours |
<10 | 10-15 mg/kg | Repeat dose depending on concentration* |
Intermittent hemodialysis | ||
Peritoneal dialysis | ||
Continuous renal replacement therapy | 15 mg/kg | Repeat dose depending on concentration* |
* The appropriate dosing intervals and subsequent doses depend largely on the RRT procedure used and should be determined based on the vancomycin serum concentration and residual renal function. Depending on the clinical situation, it may be considered to withhold the next dose until the vancomycin concentration in the blood is determined. Patients with liver problemsThere is no need to adjust the dose in patients with liver failure. PregnancyIn the case of pregnant women, it may be necessary to significantly increase the doses to achieve therapeutic vancomycin concentrations in the serum. Obese patientsIn obese patients, the initial dose should be adjusted individually based on the total body weight, just like in patients with normal body weight.
Patients 12 years and olderTreatment of Clostridium difficileinfection (CDI) In the case of the first episode of non-severe CDI, the recommended dose of vancomycin is 125 mg every 6 hours for 10 days. The dose may be increased to 500 mg every 6 hours for 10 days in the case of severe or complicated disease. The maximum daily dose should not exceed 2 grams. In patients with multiple recurrences, it may be considered to treat the current episode of CDI with vancomycin at a dose of 125 mg four times a day for 10 days, followed by a gradual reduction in dose to 125 mg per day or the use of a pulsing regimen, i.e., 125-500 mg/day every 2-3 days for at least 3 weeks. Newborns, infants, and children under 12 years of ageThe recommended dose of vancomycin is 10 mg/kg every 6 hours for 10 days. The maximum daily dose should not exceed 2 grams. The duration of vancomycin treatment may need to be adjusted based on the clinical course of the disease in the individual case. Whenever possible, the use of the suspected antibacterial agent should be discontinued. Adequate fluid and electrolyte supplementation should be ensured. Monitoring vancomycin serum concentrations The frequency of monitoring the therapeutic concentration of the medicine should be adjusted individually based on the clinical situation and response to treatment; the frequency of sampling may range from daily sampling in some unstable hemodynamic patients to at least once a week in stable patients with a visible response to treatment. In patients undergoing intermittent hemodialysis, the vancomycin concentration should be determined before the start of the hemodialysis session. Monitoring vancomycin serum concentrations after oral administration should be performed in patients with inflammatory bowel disease. The minimum therapeutic concentration of vancomycin in the blood should be 10-20 mg/l, depending on the site of infection and the susceptibility of the pathogen. Clinical laboratories usually recommend a minimum concentration of 15-20 mg/l, ensuring better coverage of microorganisms classified as susceptible with an MIC ≥1 mg/l. In predicting individual dosing required to achieve the appropriate AUC value, model-based methods may be useful. A model-based approach can be used when calculating the individual initial dose and when modifying doses based on TDM results. Method of administration Intravenous administrationVancomycin is usually administered intravenously in the form of intermittent infusions; the dosing recommendations presented in this section for the intravenous route refer to this method of administration. Vancomycin should be administered only by slow intravenous infusion lasting at least 1 hour or at a maximum rate of 10 mg/min (longer period) in a sufficiently diluted solution (at least 100 ml per 500 mg). Patients with restricted fluid intake may receive a solution of 500 mg/50 ml, but at this higher concentration, the risk of infusion-related adverse reactions is increased. Continuous infusion of vancomycin may be considered, e.g., in patients with unstable vancomycin clearance. Oral administrationThe contents of the vial can be used to prepare an oral solution. The oral solution is prepared by dissolving the contents of the vial (500 mg of vancomycin) in 30 ml of water. The appropriate dose can be administered to the patient to drink or through a nasogastric tube. Syrup can be added to the solution to improve the taste. Preparation of the infusion solutionThe contents of the vial should be dissolved in 10 ml of water for injection. 1 ml of the resulting solution contains 50 mg of vancomycin. The solution can be further diluted depending on the method of administration. Multiple infusions The prepared solution should be diluted in 100 ml of 5% glucose solution or 0.9% sodium chloride solution. The vancomycin concentration in the resulting solution should not exceed 5 mg/ml. The solution should be administered intravenously slowly, at a maximum rate of 10 mg/min, over at least 60 minutes. Continuous infusion It should be used only when multiple infusions are not possible. The vancomycin solution with a concentration of 50 mg/ml should be diluted in a sufficient volume of 5% glucose solution or 0.9% sodium chloride solution so that the patient receives the prescribed daily dose in a drip infusion over 24 hours. Stability and storage conditions of solutionsThe prepared solution can be stored for up to 24 hours at a temperature of 2°C to 8°C. For microbiological reasons, the prepared solution should be used immediately. Otherwise, the user is responsible for the storage time and conditions of the prepared solution. IncompatibilitiesThe solution has a low pH and may be physically or chemically unstable when mixed with other substances. Vancomycin solutions should not be mixed with other solutions, except for those whose compatibility has been reliably established. Mixing vancomycin with alkaline solutions should be avoided. It is not recommended to use and mix vancomycin solutions with chloramphenicol, corticosteroids, methicillin, heparin, aminophylline, cephalosporin antibiotics, and phenobarbital. OverdoseIn the event of an overdose, it can be expected that the effects will be due to high vancomycin concentrations in the serum (ototoxic and nephrotoxic effects). Supportive treatment is recommended to maintain renal function. Vancomycin is poorly removed from the blood by hemodialysis or peritoneal dialysis. There have been reports of limited benefit from using hemofiltration with Amberlite XAD-4 resin.
Antibiotics are used to treat bacterial infections. They are ineffective against viral infections. If a doctor has prescribed antibiotics for the patient, they are necessary to treat the current illness. Despite antibiotic treatment, some bacteria may survive or multiply. This phenomenon is called resistance; it causes antibiotic treatment to be ineffective in some cases. Improper use of antibiotics promotes the development of resistance. The patient may also facilitate the development of resistance and thus delay recovery or reduce the effectiveness of antibiotic therapy if they do not follow the proper:
To maintain the effectiveness of this medicine, you should:
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.